Choriofactor 5000 IU/vial (IM/SC Injection)

5000 IU vial: ৳ 2,300.00

Medicine Details

Category	Details
Generic	Human chorionic gonadotrophin
Company	Biofactor gmbh germany

Ovulation induction in infertility due to anovulation or impaired follicle-ripening in females
Preparation of follicles for puncture in controlled ovarian hyperstimulation programs (ART) in females
Luteal phase support in females
Threatened and habitual abortion in females
Hypogonadotropic hypogonadism in males
Delayed puberty associated with insufficient gonadotropic pituitary function in males
Cryptorchidism treatment (not due to anatomical obstruction) in males
Treatment of oligospermia in males

Highly Purified Human Chorionic Gonadotrophin has LH activity
LH indispensable in normal female and male gamete growth and maturation, and gonadal steroid production
Human Chorionic Gonadotrophin given as a substitute for the endogenous mid-cycle LH surge to induce the final phase of follicular maturation, leading to ovulation in females
Human Chorionic Gonadotrophin given as a substitute for endogenous LH during the luteal phase in females
Human Chorionic Gonadotrophin given to stimulate Leydig cells to promote the production of testosterone in males
Maximal Human Chorionic Gonadotrophin plasma levels reached approximately six hours after a single injection
Human Chorionic Gonadotrophin is approximately 80 percent metabolized, predominantly in the kidneys
Following intramuscular injection (IM) the apparent elimination half-life of Human Chorionic Gonadotrophin is about 2 days

Reconstituted Human Menopausal Gonadotrophin solution should be slowly administered intramuscularly in females
Dosage regimen for ovulation induction and preparation of follicles for puncture ranges from 5000-10000IU Human Menopausal Gonadotrophin
Luteal phase support requires repeat injections of 2500 to 5000IU in females
Threatened & habitual abortion treatment involves giving 5000IU Human Menopausal Gonadotrophin as deep intramuscular injection twice weekly in females
Hypogonadotropic hypogonadism treatment involves 2500 to 5000 IU Human Menopausal Gonadotrophin, two times per week in males

Known or suspected androgen-dependent tumors, such as prostatic carcinoma or breast carcinoma in males

Allergic reactions
Local reactions such as pain and rash at the injection site
Generalized reactions such as rash and fever
Unwanted ovarian hyperstimulation syndrome in females
Water and sodium retention occasionally seen in males
Aggravation or recurrence of latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine
Premature epiphyseal closure or precocious sexual development in prepubertal boys

Increased risk of multiple births in pregnancies occurring after induction of ovulation with gonadotropic preparations
Unwanted ovarian hyperstimulation in females
Ultrasonic assessment of follicular development and estrogen level monitoring recommended prior to FSH-treatment
Discontinue FSH-containing preparation if unwanted ovarian hyperstimulation occurs
Estrogen levels may rise rapidly
Risk of mild to severe ovarian hyperstimulation syndrome, including life-threatening cases
Induction of precocious puberty in pediatric patients treated for cryptorchidism
Monitor skeletal maturation in prepubertal boys regularly

Potential for induction of precocious puberty in pediatric patients treated for cryptorchidism
No clinical studies of Chorionic gonadotropin for injection included subjects aged 65 and over